Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis

Trial Profile

Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Mometasone (Primary) ; Amoxicillin/clavulanic acid
  • Indications Bacterial infections; Sinusitis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 21 Jun 2010 Actual patient number (237) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 07 Dec 2008 Status changed from suspended to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top